Showing 3781-3790 of 4164 results for "".
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T
- 4D Molecular Therapeutics' Gene Therapy Maintains Stable Visual Acuity in Wet AMD Patients in Phase 2 Studyhttps://modernod.com/news/new-data-shows-4d-molecular-therapeutics-gene-therapy-cuts-eylea-use-in-wet-amd-patients/2482097/4D Molecular Therapeutics announced positive interim data from the phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (AMD) patients with severe disease activity and a high treatment burden. Data presented at the Angiogenesis, Exudat
- EuroEyes Group Wins SMILE Refractive Laser Eye Surgery Awardhttps://modernod.com/news/euroeyes-group-wins-smile-refractive-laser-eye-surgery-award/2482087/LEC London announced that its parent company EuroEyes Clinic Group, has won the SMILE Laser Operations Award for conducting the highest number of SMILE (Small Incision Lenticule Extraction) laser operations in Europe last year (2023). EuroEyes performed a total of 9,550 SMILE operations
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc
- NIH: New Technique Enhances Quality Control of Lab-Grown Cells for AMD Treatmenthttps://modernod.com/news/nih-new-technique-enhances-quality-control-of-lab-grown-cells-for-amd-treatment/2482074/Researchers at the National Eye Institute (NEI) say they have improved a crucial step in the production of retinal pigment epithelium (RPE) they are testing in a clinical trial as treatment for age-related macular degeneration (AMD). Their technique combines electrochemical cell measurements
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512 for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/Alcon announced positive topline results from the two pivotal phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 93
- Alkeus’ Gildeuretinol Studied to Halt Progression of Early-Stage Stargardt Diseasehttps://modernod.com/news/alkeus-gildeuretinol-studied-to-halt-progression-of-early-stage-stargardt-disease/2482055/Alkeus Pharmaceuticals announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to 6 years in the ongoing TEASE-3 clinical trial. The first three teenage patients with early-stage Stargardt disease enrolled in the trial and treated with oral gild
- Alimera Completes Recruitment for the Synchronicity Study Evaluating Yutiqhttps://modernod.com/news/alimera-completes-recruitment-for-the-synchronicity-study-evaluating-yutiq/2482044/Alimera Sciences announced that it has completed enrollment for the company’s Synchronicity study, a prospective, open-label clinical study evaluating the safety and efficacy of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic noninfectious uveitis
- iSTAR Medical Continues European Expansion with First MINIject Surgeries in the Netherlandshttps://modernod.com/news/istar-medical-continues-european-expansion-with-first-miniject-surgeries-in-the-netherlands/2482027/iSTAR Medical announced the successful first implantations of MINIject, the company’s bio-integrating, minimally-invasive glaucoma surgery (MIGS) device, in the Netherlands. Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ b
- Ocugen's OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of RP Associated with RHO Mutationshttps://modernod.com/news/ocugens-ocu400-receives-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-rp-associated-with-rho-mutations/2482019/Ocugen announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. “RMAT designation is a significant accomplishment for the OCU400 clinical develo